[Seite 84↓]


1. Abrams RA, Johnston-Early A, Kramer C, et al. (1981): Amplification of circulating granulocyte-monocyte stem cell nimbers following chemotherapy in patients with extensive small cell carcinoma of the lung. Cancer Res. 41: 35-41.

2. Adamson PC, Balis FM, Belasco JE, et al. (1995): A phase I trial of amifostine (WR 2721) and melphalan in children with refractory cancer. Cancer Res. 55: 4069-4072.

3. Afzal SMJ, Ainsworth EJ. (1987): Radioprotection of mouse colony forming units-spleen against heavy-charged particle damage by WR 2721. Radiat Res 109: 118-126.

4. Alberts DS, Noel JK. (1995): Cisplatin-associated neurotoxicity: Can it be prevented? Anticancer Drugs 6: 369-383.

5. Anand AJ, Bashey B. (1993): Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27: 1519-1525

6. Ashihara E, Shimazaki C, Yamagata N, et al (1994): Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 13: 377-381.

7. Avril MF, Ortoli JC, Fortier-Beaulieu M, et al. (1992): High-dose cisplatin an WR 2721 in metastatic melanoma. Proc Am Soc Clin Oncol 11: 344.

8. Bamberg M, Schmoll HJ, Weissbach L, et al (1997): Interdisziplinäre Konsensus-Konferenz zur "Diagnostik und Therapie von Hodentumoren". Strahlenther Onkol 173: 397-406.

9. Betticher DC, Anderson H, Ranson M, et al. (1995): Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer, a randomized phase II study. Br J Cancer 72: 1551-1555.

10. Beyer J, Grabbe J, Lenz K, et al (1992): Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion. Bone Marrow Transplant 10: 491-494.

11. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1994): Treatment intensification in disseminated germ-cell tumors. World J Urol 12: 207-213.

12. Beyer J, Schwella N, Zingsem J, et al (1995): Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 13: 1328-1335.

13. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1996): Hochdosischemotherapie bei Hodentumoren. Onkologe 2: S28-S32.

[Seite 85↓]

14. Beyer J, Kramar A, Mandanas R, et al (1996): High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14: 2638-2645.

15. Beyer J, Kingreen D, Krause M, et al (1997): Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79: 161-168.

16. Beyer J, Rick O, Weinknecht S, et al (1997): Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 20: 813-819.

17. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1998): Salvagetherapie rezidivierter und refraktärer Hodentumoren. Onkologe 4: 541-546.

18. Beyer J, Schmoll HJ (1998): Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. Onkologe 4: 518-523.

19. Beyer J, Stenning S, Gerl A, et al (2002): High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis. Annals of Oncol 13: 599-605.

20. Bhatia S, Abonour R, Porcu P, et al. (2000): High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18: 3346-3351

21. Blijham G, Spitzer G, Litam J, et al (1981): The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer 17: 433-441.

22. Bokemeyer C, Beyer J, Metzner B, et al. (1996): Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34.

23. Bokemeyer C, Schmoll HJ, Kuczyk MA, et al (1995): Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87: 58-60.

24. Bokemeyer C, Hartmann JT, Kanz L (1997): Prävention cisplatininduzierter Chemotherapietoxizität durch Amifostin. Arzt und Krankenhaus 2: 57-56.

25. Bokemeyer C, Harstrick A, Beyer J, et al. (1998): The use of doseintensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors: German Testicular Cancer Study Group. Semin Oncol 25: 24-32.

26. Bokemeyer C, Kollmannsberger C, Meisner C, et al. (1999): First-line High-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17: 3450-3456.

[Seite 86↓]

27. Bokemeyer C, Beyer J, Metzner B, et al. (1996): Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34.

28. Bokemeyer C, Frank B, van Rhee J, et al. (1993): Peripheral neuropathy following cancer chemotherapy. Tumordiagn Ther 24: 351.

29. Bokemeyer C, Hartmann J, Fels L, et al. (1997): Amifostine protects against early cisplatin-induced renal damage and enhances CD34+ cell numbers for PBSC collection. Proc Am Soc Clin Oncol 16: 47a

30. Bokemeyer C, Gerl A, Schöffski P, et al. (1999): Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 512-516.

31. Bokemeyer C, Berger CC, Kuczyk MA, et al (1996): Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923-2932.

32. Bosl GJ, Yagoda A, Golbey RB, et al (1985): Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 78: 423-428.

33. Bosl G, Motzer RJ (1997): Testicular germ-cell cancer. N Engl J Med 337: 242-253.

34. Broun ER, Nichols CR, Einhorn LH, Tricot GJK (1991): Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 68: 1513-1515.

35. Broun ER, Nichols CR, Tricot G, et al (1991): High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 7: 53-56.

36. Broun ER, Nichols CR, Kneebone P, et al (1992): Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117: 124-128.

37. Broun ER, Nichols CR, Turns M, et al (1994): Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73: 1716-1720.

38. Broun ER, Nichols CR, Mandanas R, et al (1995): Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 16: 353-358.

39. Brugger W, Bross K, Frisch J, et al. (1992): Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 79: 1193-1200.

[Seite 87↓]

40. Budd GT, Ganapathi R, Adelstein DJ, et al. (1997): Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 80: 1134-1140.

41. Buntzel J, Glatzel M, Kuttner K, et al. (1998): Selective cytoprotection with amifostine in concurrent radiochemotherapy of head and neck cancer. Ann Oncol 9: 505-509.

42. Capelli D, Santini G, De Souza C, et al. (2000): Amifostine can reduzed mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 110: 300-107.

43. Carlo-Stella C, Dodero A, Regazzi E, et al. (1998): Amifostine enhances chemotherapy-elicited peripheral blood progenitor cell mobilisation. Proc Am Soc Clin Oncol 17: 78a

44. Cavaletti G, Bogliun G, Crespi V, et al (1997): Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 15: 199-206.

45. Chauncey TR, Gooley TA, Lloid ME, et al. (2000): Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Am J Clin Oncol 23: 406-411.

46. Cockroft DW, Gault MH (1976): Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.

47. Cooper MA, Einhorn LH (1995): Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 13: 1167-1169.

48. Cox DR (1972): Regression models and life-tables. J R Stat Soc (B) 34: 187-220.

49. Demuynck H, Delforge M, verhoef G, et al. (1993): Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF of rhG-CSF. Br J Haematol 90: 384-392.

50. De Santis M, Bokemeyer C, Becherer A, et al (2001): Predictive impact of 2-Fluoro-2-Deoxy-D-Glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19: 3740-3744.

51. Dieckmann KP, Kreuser ED (1991): Aktueller Stand der Chemotherapie von Keimzelltumoren. Urologe A 30: 45-54.

[Seite 88↓]

52. Donohue JP, Birhle R, Foster RS (1992): Evolving concepts in surgical management of testis cancer. Cancer Treat Res 59: 89-97.

53. Donohue JP, Fox EP, Williams SD, et al (1994): Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: Outcome analysis. World J Urol 12: 190-195.

54. Douay L, Hu C, Giarratana MC, et al. (1995): Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging. Blood 86: 2849-2855.

55. Dreger P, Marquardt P, Haferlach T, et al. (1993): Effective mobilization of peripheral blood progenitor cells with „DexaBEAM“ and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 68: 950-957.

56. Dührensen U, Villeval JL, Boyd J, et al (1988): Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 2074-2081.

57. Einhorn LH (1990): Treatment of testicular cancer: a new and improved model. J Clin Oncol 8: 1777-1781.

58. Einhorn LH, Stender MJ, Williams SD. (1999): Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17: 509-511.

59. Farhat F, Culine S, Theodore C, et al (1996): Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 77: 1193-1197.

60. Fields K, Elfenbein GJ, Lazarus H, et al (1995): Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 13: 323-332.

61. Fitzharris BM, Kaye SB, Saverymuttu S, et al. (1980): VP-16 as single agent in advanced testicular tumors. Eur J Cancer 16: 1193-1197.

62. Fossa SD, Aass N, Ous S, et al. (1989): Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 142: 1239-1242.

63. Fossa SD, Stenning SP, Gerl A, et al (1999): Prognostic factors in patients relapsing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392-1399.

64. Fox EP, Weathers TD, Williams SD, et al (1993): Outcome analysis of patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294-1299.

[Seite 89↓]

65. Freyer G, Hennebert P, Awada A, et al. (2002): Influence of amifostine on th toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Clin Cancer Res 8: 95-102.

66. Gale RP, Henon P, Huttner C (1992): Blood stem cell transplantation come of age. Bone Marrow Transplant 9: 151-155.

67. Gelmon K, Eisenhauer E, Bryce C, et al. (1999): Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17: 3038-3047.

68. Gerl A, Clemm C, Schmeller N, et al (1995): Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026-1032.

69. Glover D, Glick JH, Weiler C, et al. (1986): WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 4: 584-588.

70. Glover D, Glick JH, Weiler C, et al. (1987): WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5: 574-578.

71. Goodnough L, Brecher ME, Kanter MH, AuBuchon JP (1999): Transfusion medicine. N Engl J Med 340: 438-447.

72. Goren MP, Wright RK, Pratt CB, et al (1987): Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 47: 1457-1460.

73. Gradishar WJ, Stephenson P, Glover DJ, et al. (2001): A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma. Cance 92: 2517-2522.

74. Gregg RW, Molepo JM, Monpetit VJA, et al. (1992): Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissue, and morphologic evidence of toxicity. J Clin Oncol 10: 795-803.

75. Groopman JE, Molina JM, Scadden DT, et al. (1989): Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 321: 1449-1459.

76. Gulati SC (1994): Did we focus on the most important issues in the use of growth factors and stem-cell transplantation. J Clin Oncol 12: 650-652.

77. Haas R, Möhle R, Frühauf S, et al (1994): Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83: 3787-3794.

[Seite 90↓]

78. Hainsworth JD, Williams SD, Einhorn LE, Birch R, et al (1985): Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group Trial. J Clin Oncol 3: 666-671.

79. Harding MJ, Paul J, Gillis CR, Kaye SB (1993): Management of malignant teratoma: does referral to a specialist unit matter? Lancet 341: 999-1002.

80. Harstrick A, Schmoll HJ, Wilke H, et al (1991): Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9: 1549-1555.

81. Hartmann JT, von Vangerow A, Fels LM, et al. (2001): A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 84: 313-320.

82. Hartmann JT, Schmoll HJ, Kuczyk MA, et al (1997): Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular cell tumors. Ann Oncol 8: 531-538.

83. Henon PR, Liang H, Beck-Wirth G, et al. (1992): Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 9: 285-291.

84. Hildebrandt MO, Blaser F, Beyer J, et al (1998): Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase_polymerase chain reaction techniques. Bone Marrow Transplant 22: 771-775.

85. Hinton S, Catalano P, Einhorn L, et al. (2002): Phase II Study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20: 1859-1863.

86. Hölzel D, Altwein JE (1991): Hodentumoren. Ist der Rückgang der Mortalität in der Bundesrepublik Deutschland zu langsam erfolgt? Deutsch Ärztebl 8 8: B2694-B2700.

87. Hölzel D, Klamert A, Schmidt M. Krebs. Häufigkeiten, Befunde und Behandlungsergebnisse. München: Zuckschwerdt Verlag, 1996.

88. Horwich A (1995): Salvage therapy of germ cell tumours. Br J Cancer 71: 901-903.

89. ICH. Harmonised tripartite guideline for good clinical practice. Richmond, Surrey, UK: Brookwood Medical Publications Ltd, 1997.

90. International Germ Cell Cancer Collaborative Group (1997): International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603.

[Seite 91↓]

91. Johnson PWM, Muers MF, Peak MD, et al. (2001): A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. Br J Cancer 84: 19-24.

92. Josefsen D, Ous S, Hoie J, Stenwig AE, Fossa SD (1993): Salvage treatment in male patients with germ cell tumours. Br J Cancer 67: 568-572.

93. Kaplan EL, Meier P (1958): Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.

94. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948): The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634-656.

95. Kemp G, Rose P, Lurain J, et al. (1996): Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112.

96. Kessinger A, Armitage JO (1991): The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77: 211-213.

97. Klumpp TR, Mangan KF, Goldberg SL, et al (1995): Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 13: 1323-1327.

98. Kollmannsberger C, Beyer J, Droz JP, et al (1998): Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386-3391.

99. Kollmannsberger C, Rick O, Derigs H-G, et al. (2002): Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. (GTCSG). J Clin Oncol 15: 2031-2037.

100. Kollmannsberger C, Schleucher N, Rick O, et al. (2002): Analysis of salvage treatment for germ cell cancer patients relapsing after primary high-dose chemotherapy plus autologous stem cell support. J Clin Oncol, submitted.

101. Kotasek D, Shepherd KM, Sage RE, et al. (1992): factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma, and solid tumors. Bone Marrow Transplant 9: 11-17.

102. Lampe H, Dearnaley D, Price A, et al (1995): High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer 31A: 717-723.

103. Ledermann JA, Holden L, Newlands ES, et al (1994): The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 74: 225-230.

[Seite 92↓]

104. Levine EG, Raghavan D (1991): Treatment of refractory testis cancer: salvage or savage chemotherapy? Eur J Cancer 27: 932-936.

105. Linkesch W, Krainer M, Wagner A (1992): Phase I/II trial of ultrahigh dose carboplatin, etoposide, cyclophosphamide with ABMT in refractory nonseminomatous germ cell tumors (GCT). Proc Am Soc Clin Oncol 11: 196 (abstract 600).

106. List AF, Heaton R, Glinsmann-Gibson B, et al. (1998): Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 12: 1596-1602.

107. List AF, Brasfield F, Heaton R, et al. (1997): Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90: 3364-3369.

108. Loehrer PJ, Einhorn LH, Williams SD (1986): VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4: 528-536.

109. Loehrer PJ, Gonin R, Nichols CR, et al (1998): Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500-2504.

110. Lohrmann HP, Schreml W, Lang M, et al. (1978): Changes of granulopoiesis during and after adjuvant chemotherapy of breast cancer. Br J Haematol 40: 369-381.

111. Mantel N (1966): Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Treat Rep 50: 163-170.

112. McCaffrey JA, Mazumdar M, Bajorin D, et al (1997): Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559-2563.

113. Miller KD, Loehrer PJ, Gonin R, et al. (1997): Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15: 1427-1431.

114. Mollman JE, Glover DJ, Hogan WM, et al. (1988): Cisplatin neutopathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192-2195.

115. Mollman JE. (1990): Cisplatin neurotoxicity. New Engl J Med 11: 126-127.

116. Morrow GR, Hickok JT, Rosenthal SN (1995): Progress in reducing nausea and emesis. Cancer 76: 343-357.

117. Motzer RJ, Cooper K, Geller NL, et al (1990): The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66: 2476-2481.

[Seite 93↓]

118. Motzer RJ, Gulati SC, Crown JP, et al (1992): High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: Early intervention is better tolerated. Cancer 69: 550-556.

119. Motzer RJ, Mazumdar M, Bosl GJ, et al (1996): High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098-1105.

120. Motzer RJ, Sheinfeld J, Mazumdar M, et al. (2000): Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413-2418.

121. Motzer RJ, Bajorin DF, Schwartz LH, et al. (1994): Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277-2283.

122. Motzer RJ, Mazumdar M, Sheinfeld J, et al. (2000): Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173-1180.

123. Mulder POM, De Vries EGE, Schraffordt Koops H, et al (1988): Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 24: 675-679.

124. Murphy BR, Breeden ES, Donohue et al (1993): Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11: 324-329.

125. Newlands ES, Bagshawe KD (1977): Epipodophyllin derivative (VP16-213) in malignant teratomas and chorioncarcinomas. Lancet 2: 87.

126. Newlands ES, Bagshawe KD, Begent RHJ, et al (1986): Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol 58: 307-314.

127. Nichols CR, Tricot G, Williams SD, et al (1989): Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932-939.

128. Nichols CR, Andersen J, Lazarus HM, et al (1992): High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 10: 558-563.

129. Nichols CR, Roth BJ, Loehrer PJ, et al (1994): Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 21: 102-108.

[Seite 94↓]

130. Nichols CR, Catalano PJ, Crawford ED, et al (1998): Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an eastern cooperative oncology group, southwest oncology group, and cancer and leukemia group B study. J Clin Oncol 16: 1287-1293.

131. Peckham MJ, Horwich A, Easton DF, et al. (1988): The management of advanced tesicular teratoma. Br J Urol 62: 63-68.

132. Pettengell R, testa NG, Swindell R, et al. (1993): Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin´s lymphoma. Blood 82: 2239-2248.

133. Pizzocaro G, Pasi M, Salvioni R, et al (1985): Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. Cancer 56: 2399-2403.

134. Planting AST, Catimel G, de Mulder PHM, et al. (1999): Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 10: 693-700.

135. Pont J, Holtl W, Weissbach L, et al (1997): Hochdosischemotherapie und Reinfusion von hämatopoetischen Stammzellen bei fortgeschrittenen Keimzelltumoren mit schlechter Prognose - Stand 1996. Urologe A 36: 561-564.

136. Porcu P, Bhatia S, Einhorn LH. (2000): Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18: 1181-1186.

137. Poplin EA, LoRusso P, Lokich JJ, et al. (1994): Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415-419.

138. Postma TJ, Vermorken JB, Liefting AJM, et al (1995): Paclitaxel-induced neuropathy. Ann Oncol 6: 489-494.

139. Rick O, Beyer J, Kingreen D, et al (1998): High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer 34: 1883-1888.

140. Rick O, Beyer J, Kingreen D, et al (2000): Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Ann Hematol 79: 681-686.

141. Rick O, Siegert W, Beyer J. (2001): Chemotherapy in patients with metastatic or relapsed germ-cell tumours. Cancer Treatment Rev 27: 283-288.

[Seite 95↓]

142. Rick O, Bokemeyer C, Beyer J, et al. (2001): Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa(CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19: 81-88.

143. Rick O, Bokemeyer C, Weinknecht S, et al. (2002): Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell tumors. Proc Am Soc Clin Oncol 22: abstract 1563.

144. Rick O, Schwella N, Beyer J, et al. (2001): PBPC mobilisation with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial. Transfusion 41: 196-200.

145. Rick O, Beyer J, Schwella N, et al. (2001): Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 12: 1151-1155.

146. Rick O, Beyer J, Schwella N, et al. (2002): Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor. Ann Hematol

147. Rodenhuis S, Westermann A, HoltkampMJ, et al. (1996): Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14: 1473-1483.

148. Roberts MM, To LB, Gillis D, et al (1993): Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 12: 469-475.

149. Rosti G, Albertazzi L, Salvioni R, et al (1992): High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol 3: 809-812.

150. Rosti G, Pico JL, Wandt H, et al (2002) High-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy fo advanced germ cell tumors; first results of a prospective randomised trial of the European Group for Blood and Morrow Transplantation EBMT): IT-94 study. Proc Am Soc Clin Oncol 21: abstract 716.

151. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al (1993): Clinical toxicities encountered with paclitaxel (TAXOL). Semin Oncol 20: 1-15.

152. Sachs L. Angewandte Statistik. Heidelberg: Springer-Verlag, 1992.

153. Sandler A, Loehrer P: Salvage therapy and autologous bone marrow transplantation, in Horwich A (ed): Testicular cancer. 2 ed. London, Chapman and Hall Medical, 1996, pp 307-318.

[Seite 96↓]

154. Saxman SB, Nichols CR, Einhorn LH (1994): Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12: 1390-1393.

155. Scambia G, Panici PB, Pierelli L, et al (1993): Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. Eur J Cancer 29A: 1518-1522.

156. Scheid C, Pettengell R, Ghielmini M, et al (1995): Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin`s lamphoma. Bone Marrow Transplant 15: 901-906.

157. Schiller JH, Storer B, Berlin J, et al. (1996): Amifostine, Cisplatin, and Vinblastine in metastatic non-small cell lung cancer: A report of high response rates and prolonged survival. J Clin Oncol 14: 1913-1921.

158. Schuchter L, et al. (1995): Ethyol and escalating doses of taxol. Presented at th 8th European Cancer Conference. Paris, France.

159. Schwartzberg L, Birch R, Hazelton B, et al. (1992): Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1: 317-327.

160. Schwella N, Rick O, Meyer O, et al. (1998): Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcoma. Bone Marrow Transplant 21: 863-868.

161. Schwella N, Huhn D. (1998): Mobilisation und Separation autologer Blutstammzellen. Der Onkologe 4: 639-648.

162. Schwella N, Beyer J, Schwaner I, et al (1996): Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 14: 1114-1121.

163. Schwella N, Beyer J, Rick O, et al. (1998): Blood progenitor cell mobilization with paclitaxel (Taxol) in patients with germ cell cancer (abstract). Ann Hematol 77 (Suppl 2): 161.

164. Serke S, Van Leesen A, Huhn D (1998): Quantitative fluorescence flow cytometry: a comparison of the three techniques for direct and indirect immunofluorescence. Cytometry 33: 179-187.

165. Shpall, EJ, Stemmer SM, Hami L, et al. (1994): Amifostine (WR-2721) shortens the engraftment periode of 4-Hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132-3137.

[Seite 97↓]

166. Siegert W, Beyer J (1998): Germ cell tumors: Dose-intensive therapy. Semin Oncol 25: 215-223.

167. Siegert W, Beyer J, Strohscheer I, et al (1994): High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12: 1223-1231.

168. Sigdestad CP, Grdina DJ, Connor AM, et al. (1986): A comparison of radioprotection from three neutron sources and 60Co by WR 2721 and WR 151327. Radiat Res. 106: 224-233.

169. Socinski MA, Elias A, Schnipper L, et al (1988): GM-CSF expands the circulating hematopoietic progenitor cell compartment in man. Lancet 2: 1194-1198.

170. Speicher LA, Krutzsh M, Wymer J, et al (1995): Amifostine does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Proc Amer Ass Cancer Res 36: 1727.

171. Spencer CM, Goa KL (1995): Amifostine: A review of ist pharmacodynamic and pharmacocinetic Properties, and therapeutical potential as a rdioprotector and cytotoxic chemoprotector. Drugs 50: 1001-1031.

172. Spitzer G, Adkins DR, Spencer V, et al (1994): Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12: 661-670.

173. Steyerberg EW, Donohue JP, Gerl A, et al (1997): Residual masses after chemotherapy for metastatic testicular cancer: The clinical implications of the association between retroperitoneal and pulmonary histology. J Urol 158: 474-478.

174. Steyerberg EW, Keizer HJ, Fossa SD, et al. (1995): Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177-1187.

175. Steyerberg EW, Gerl A, Fossa SD, et al. (1998): Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269-274.

176. Stiff PJ, Murgo AJ, Wittes RE, et al. (1983): Quantification of the peripheral blood colony forming unit-culture rise following chemotherapy. Could leukocytaphereses replace bone marrow for autologous transplantation? Transfusion 23: 500-503.

177. Thadhani R, Pascual M, Bonventre JV (1996): Acute renal failure. N Engl J Med 334: 1448-1460.

[Seite 98↓]

178. To LB, Haylock DN, Simmons PJ, Juttner CA (1997): The biology and clinical uses of blood stem cells. Blood 89: 2233-2258.

179. To LB, Shepperd M, Haylock DN, et al. (1990): Single high-dose of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18: 442-447.

180. To LB, Haylock DN, Kimber RJ, et al. (1984): High levels of circulating haematopietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58: 399-410.

181. To LB, Roberts MM, Haylock DN, et al. (1991): Comparison of haematologic recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 7: 173-181.

182. Treskes M, Nijtmans LGJ, Fichtinger-Shepman AMJ, et al (1992): Effects of the modulating agent WR 2721 ans ist main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43: 1013-1019.

183. Treskes M, Holwerda U, Nijtmans LGJ, et al (1992): The reversal of cisplatin-protein interactions by the modulating agent WR 2721 and ist metabolites WR 1065 and WR 33278. Cancer Chemother Pharmacol 29: 467-470.

184. Treskes M, Boven E, Holwerda U, et al. (1992): Time dependenceof the selective modulationof cisplatin-induced nephrotoxicity by WR 2721 in the mouse. Cancer Res. 52: 2257-2260.

185. Turrisi AT, Glover TJ, Hurwitz S, et al. (1986): Final report of the phase I trial of single-dose WR 2721 [S-2-(3-aminopropylamino)-ethylphosphorothioic acid]. Cancer Treat Rep. 70: 1389-1393.

186. Wadler S, Haynes H, Beitler JJ, et al. (1993): Management of hypocalcemic effects of WR 2721 administered on a daily times five schedule with cisplatin and radiation therapy. J Clin Oncol 11: 1517-1522.

187. Wang LM, Wang QW, Fernandes DJ, et al (1995): Amifostine protects MRC-5 human lung fobroplasts from taxol toxicity without reducing ist cytotoxic effect against human non-small cell lung cancer cells. Proc Am assoc cancer res 36: 288.

188. Wheeler C, Loehrer PJ, Williams SD, Einhorn LH (1986): Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28-34.

189. Williams SD, Birch R, Einhorn LH, et al (1987): Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435-1440.

[Seite 99↓]

190. Williams SD (1992): High dose therapy in germ cell tumors: when, what, and how much. Ann Oncol 3: 780-781.

191. Wilson WH, Jain V, Bryant G, et al (1992): Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10: 1712-1722.

192. Wolff SN, Johnson DH, Hainsworth JD, Greco FA (1984): High-dose VP-16-123 monotherapy for refractory germinal malignancies: a phase II study. J Clin Oncol 2: 271-274.

193. Wong GG, Witek JS, Temple PA, et al. (1985): Human GM-CSF: Molecular cloning of the complemantary DANN and purification of the natural and recombinant proteins. Science 228: 810-815.

194. Woolley PV, Ayoob MJ, Smith FP, et al. (1983): Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. I Clin Oncol 1: 198-203.

195. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication,. 1979

196. World Medical Organization Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Amended by the 41st World Medical Assembly, Hong Kong, 1989.

197. Zeller W, Gutensohn K, Stockschläger M, et al. (1996): Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin´s disease, non-Hodgkin´s lymphoma and cancer of the testis. Bone Marrow Transplant 17: 109-713.

198. Zsebo KM, Cohen AM, Murdock DC, et al. (1986): Recombinant human granulocyte colony-stimulating factor: molecular and biological characterization. Immunobiology 172: 175-184.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: